Skip to main content

Table 2 Univariate analysis of potential risk factors for HBV reactivation in HBsAg-negative DLBCL patients

From: Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival

Factor Without HBV reactivation [cases (%)] With HBV reactivation [cases (%)] P value
Total 159 6  
HBcAb    0.001
 – 110 (69.2) 0 (0)  
 + 49 (30.8) 6 (100.0)  
Age (years)    0.237
 ≤60 65 (40.9) 4 (66.7)  
 >60 94 (59.1) 2 (33.3)  
Sex    1.000
 Female 66 (41.5) 2 (33.3)  
 Male 93 (58.5) 4 (66.7)  
ECOG PS    1.000
 0–1 137 (86.2) 5 (83.3)  
 ≥2 22 (13.8) 1 (16.7)  
Bulky mass    0.343
 Yes 115 (72.3) 6 (100.0)  
 No 44 (27.7) 0 (0)  
B symptoms    1.000
 – 118 (74.2) 5 (83.3)  
 + 41 (25.8) 1 (16.7)  
Ann Arbor stage    0.211
 I–II 79 (49.7) 1 (16.7)  
 III-IV 79 (49.7) 5 (83.3)  
Liver involvement    1.000
 – 151 (95.0) 6 (100.0)  
 + 8 (5.0) 0 (0)  
Spleen involvement    0.441
 – 145 (91.2) 5 (83.3)  
 + 14 (8.8) 1 (16.7)  
Involved extranodal sites    0.627
 <2 122 (76.7) 4 (66.7)  
 ≥2 37 (23.3) 2 (33.3)  
Bone marrow involvement    1.000
 – 148 (93.1) 6 (100.0)  
 + 11 (6.9) 0 (0)  
IPI score    0.402
 0–1 68 (42.8) 1 (16.7)  
 2–5 90 (56.6) 5 (83.3)  
HBeAb    0.094
 – 146 (91.8) 4 (66.7)  
 + 13 (8.2) 2 (33.3)  
ALT    0.597
 ≤40 U/L 136 (85.5) 6 (100.0)  
 >40 U/L 23 (14.5) 0 (0)  
AST    0.526
 ≤45 U/L 141 (88.7) 5 (83.3)  
 >45 U/L 18 (11.3) 1 (16.7)  
TB    0.463
 ≤20.5 μmol/L 144 (90.6) 5 (83.3)  
 >20.5 μmol/L 15 (9.4) 1 (16.7)  
LDH    0.681
 ≤245 U/mL 97 (61.0) 3 (50.0)  
 >245 U/mL 62 (39.0) 3 (50.0)  
  1. HBV, hepatitis B virus. Other footnotes as in Table 1.